Guardant Infinity
BioPharma solutions for drug development and precision oncology
Service · OtherCompany source
Company profile
About Guardant
Guardant Health is a leading precision oncology company transforming cancer care through innovative blood-based testing solutions. The company has performed over 1,000,000 blood tests used by 12,000 doctors to inform treatment decisions and improve clinical outcomes across all stages of cancer. Their comprehensive portfolio includes Shield, a blood test for colorectal cancer screening that offers a more convenient alternative to colonoscopy and stool-based testing; Guardant360 Liquid CDx, the #1 FDA-approved liquid biopsy with the largest genomic and epigenomic panel featuring genome-wide methylation coverage; Guardant360 Tissue, an advanced tissue test integrating DNA, RNA, and epigenomics; and Guardant Reveal for minimal residual disease detection and therapy response monitoring. The company's InfinityAI platform leverages purpose-built artificial intelligence and machine learning to unlock clinically meaningful insights from complex, multimodal, longitudinal data. Guardant Health serves healthcare providers, health systems, institutional partners, and biopharma companies, delivering precision oncology solutions that enable earlier cancer detection, personalized treatment selection, and improved patient outcomes. The company is committed to conquering cancer through the power of blood tests and data-driven insights.
Company description Guardant official website
Mission. Conquering cancer through data.
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Guardant?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Advanced solid tumors
- Breast cancer
- Colorectal cancer
- Early-stage cancers
- Lung cancer
Who it serves
- BioPharma companies
- Health systems
- Healthcare providers
- Institutional partners
- Patients
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Recorded integration context: EMR integrations, Guardant Portal.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
FDA approval of Guardant360 Liquid CDx with 100x expanded footprint (May 2026). American Cancer Society recommendation of Shield blood test in colorectal cancer screening guidelines (May 2026). FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim's HERNEXEOS (June 2026).
Partnerships
Recorded partners
- American Cancer Society (Shield recommendation)
- Boehringer Ingelheim (HERNEXEOS companion diagnostic)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Guardant Reveal
Minimal residual disease detection & therapy response monitoring
Device · OtherCompany source
Guardant360 CDx
FDA-approved liquid biopsy with fast turnaround for treatment decisions
Device · OtherCompany source
Guardant360 Liquid CDx
#1 liquid biopsy with 100x expanded genomic & epigenomic footprint
Device · OtherCompany source
Guardant360 Tissue
Most advanced tissue test integrating DNA, RNA, & epigenomics
Device · OtherCompany source
InfinityAI
Purpose-driven AI and machine learning technology for precision oncology
Platform · Cloud SaaSCompany source
Shield Blood Test
Blood-based screening test for colorectal cancer
Device · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Beyond variant detection: Mismatch repair gene alterations in plasma cell-free DNA from 1,226 glioma samples, and plasma-confirmed functional deficiency in an unbiopsied pontine glioma.The journal of liquid biopsy · Dec 1, 2026
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation.Journal of medical economics · Dec 1, 2026
Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence.The journal of liquid biopsy · Dec 1, 2026
Real-world analysis of treatments, healthcare costs, and overall survival among patients with metastatic non-small cell lung cancer by molecular biomarker testing approach.Cancer treatment and research communications · Oct 16, 2026
Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy.Cancer · Oct 15, 2026
Dynamic Predictions in Non-Small Cell Lung Cancer Using Joint Modeling of Longitudinal and Time-To-Event Outcomes Data.Cancer medicine · Oct 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Over 1,000,000 blood tests performed
Clinical utilization by 12,000 doctors
7-day turnaround time
Guardant360 Liquid CDx and Guardant360 CDx results
40% fewer slides required
Guardant360 Tissue vs industry standard
92% less surface area required
Guardant360 Tissue vs industry standard
100x expanded genomic footprint
Guardant360 Liquid CDx vs Guardant360 CDx
Boehringer Ingelheim
Companion diagnostic for HERNEXEOS therapy
FDA approval of Guardant360 CDx as companion diagnostic for HERNEXEOS
American Cancer Society
Colorectal cancer screening guidelines update
Shield Blood Test recommended in updated colorectal cancer screening guidelines
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Helmy Eltoukhy
Co-CEO
06 · Company updates
Updates from Guardant
Recent articles published on Guardant's official website.
Guardant Health co-CEO Helmy Eltoukhy on breast cancer test
Read on GuardantOne-on-one with CEO of company behind cancer blood test
Read on GuardantNew Drug Approved for Advanced Breast Cancer After Other Treatments Fail
Read on GuardantThe Future of Colorectal Cancer Screening: Reaching the Unscreened
Read on GuardantAmerica’s most innovative businesses 2027
Read on Guardant07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.